1-Pentanamine, 1-methyl, N-propyl

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Pentanamine, 1-methyl, N-propyl
• 英文别名: N-methyl-N-propylpentan-1-amine
• 化学式: C₉H₂₁N
• 分子量: 143.27
• InChiKey: OOVHIYXQHWBXPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Pentanamine, 1-methyl, N-propyl 、 氢氟酸 以4%的产率得到
  参考文献：
  名称：

  ABE, TAKASHI;HAYASHI, EIJI;BABA, HAJIME;NAGASE, SHUNJI, J. CHEM. SOC. JAP., CHEM. AND IND. CHEM., 1985, N 10, 1980-1987

  摘要：

  DOI：

文献信息

• METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH
  申请人：Pierce William M.

  公开号：US20080221070A1

  公开（公告）日：2008-09-11

  Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R T ), having an affinity for bone; a Bone Active Portion (R A ) for interacting with and affecting bone; a Linking Portion (R L ) connecting the Bone Targeting Portion and the Bone Active Portion. The Bone Active Portion is derived from an estrogenic agent. Compounds can also include a Blocking Group (R P ) that reduces or eliminates the estrogenic activity of the Bone Active Portion.

  提供了针对骨骼的化合物和方法。这些化合物可以包括针对骨骼的部分（RT），具有与骨骼的亲和力；用于与骨骼相互作用并影响骨骼的活性部分（RA）；连接针对骨骼部分和活性部分的连接部分（RL）。活性部分来源于雌激素类药物。化合物还可以包括减少或消除活性部分雌激素活性的阻断基团（RP）。
• Process for the preparation of biphosphonic acids
  申请人：Danda Subba Reddy

  公开号：US20070173645A1

  公开（公告）日：2007-07-26

  An improved process for bisphosphonylation of acids, substituted acids to obtain compounds with the formula using phosphorus trihalide, phosphorus acid, in presence of phenolic compounds as diluent/solvent.

  一种改进的方法用于通过磷三卤化物、磷酸在苯酚化合物作为稀释剂/溶剂的存在下对酸、取代酸进行双膦酸化反应，以获得具有以下公式的化合物。
• NOVEL PROCESS
  申请人：Gore Vinayak G.

  公开号：US20090198062A1

  公开（公告）日：2009-08-06

  The present invention relates to a process for the preparation of bisphosphonic acids and salts thereof, in particular monosodium salts thereof. The invention also relates to the conversion of the bisphosphonic acids to their sodium salts using an aqueous-organic solvent system. The present invention further relates to the conversion of variable hydrate forms of risedronic acid monosodium salt into a pharmaceutically acceptable hemipentahydrate form by crystallization using an aqueous-organic solvent system.

  本发明涉及一种制备双膦酸及其盐，尤其是单偏磷酸钠盐的方法。本发明还涉及使用水-有机溶剂体系将双膦酸转化为其钠盐的方法。本发明还涉及使用水-有机溶剂体系通过结晶将不同水合形式的瑞舒地尼酸单偏磷酸钠盐转化为药学上可接受的半五水合物形式的方法。
• Antiviral Indoles
  申请人：Stansfield Ian

  公开号：US20100076046A1

  公开（公告）日：2010-03-25

  Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and R 1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

  公式（I）中的化合物，其中A，B，D，M，Ar，W，X，Y，Z和R1的定义如下，对于预防和治疗丙型肝炎感染是有用的。本文公开了这些化合物的制备方法、含有它们的制药组合物以及它们在医学上的使用。
• PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
  申请人：Kilburn John Paul

  公开号：US20110312949A1

  公开（公告）日：2011-12-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟基类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为制药组合物的用途。还描述了一种新型的取代酰胺类化合物，它们在治疗中的应用，包括含有这些化合物的制药组合物，以及它们在制药方面的应用。这些化合物是11βHSD1活性的调节剂，更具体地说是抑制剂，并且可能在治疗、预防和/或预防需要降低细胞内活性糖皮质激素浓度的一系列医学疾病中有用。